Perspective Therapeutics, Inc.
- Jurisdiction
United States - LEI
5493005LRKM6BCABC605 - ISIN
US46489V3024 (CATX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€491.30K - Gross margin
-150.2% - EBIT
-€90.71M - EBIT margin
-18,462.7% - Net income
-€96.93M - Net margin
-19,728.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: November 10, 2022 (Q1 2023)